Option chain shows key data for Eupraxia Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Eupraxia Pharmaceuticals.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock, Option Chain

Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.

xr:d:DAFj0FUZspA:2,j:5351515556,t:23052408

News

Pre-Market Outlook

Markets

Movers

AKTS

BNED

BRLS

CJET

CRKN

EDBL

EPRX

LFST

LMFA

MBIO

MGOL

MGRX

RZLT

SINT

URBN

VRPX

VSAT

VSME

XYLO

Why Urban Outfitters Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket

Penny Stocks

Small Cap

Trading Ideas

AEHL

ALLR

AUUD

BCAN

BRCC

CCTG

DXYZ

ESPR

FAAS

FLGC

GLMD

LGVN

MDIA

MSTR

NCPL

RELI

XXII

ZOOZ

Shares of  Esperion Therapeutics, Inc.  (NASDAQ: ESPR) shares rose sharply during today’s pre-market trading after the company presented new data from CLEAR outcomes at ACC.24 highlighting value of NEXLETOL® tablets in diverse populations.

Why Esperion Therapeutics Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket

Eupraxia Pharmaceuticals Inc. - Common Stock

Eupraxia Pharmaceuticals Inc

Eupraxia Pharmaceuticals Inc Ordinary Shares

MITQ

Moving iMage Technologies Shares Halted On Circuit Breaker To The Downside, Stock Now Up 68%

WIIM

GIFT

Giftify shares are trading higher after the company announced the pricing of a $600,000 public offering of 600,000 shares of its common stocks with no warrants at $1.00 per share.

Macro Economic Events

Economics

Federal Reserve

Goldman Sachs CEO Says The Fed's Current Stress Testing Creates Uncertainty

<p>RBC Capital  analyst Sean Dodge   maintains Health Catalyst (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCAT#NASDAQ">HCAT</a>) with a Sector Perform and lowers the price target from $9 to $7.</p>


Price Target

Analyst Ratings

HCAT

RBC Capital Maintains Sector Perform on Health Catalyst, Lowers Price Target to $7

BECN

Beacon Roofing Supply shares are trading higher after QXO announced a proposal to acquire the company for $125.25 per share in cash for a total valuation of approximately $11 billion.

<p>Evercore ISI Group  analyst James West   maintains Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) with a Outperform and lowers the price target from $43 to $35.</p>


Evercore ISI Group Maintains Outperform on Halliburton, Lowers Price Target to $35

<p>Financial giants have made a conspicuous bullish move on Apple. Our analysis of options history for Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) revealed 12 unusual trades.</p>
<p>Delving into the details, we found 50% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $195,700, and 8 were calls, valued at $334,035.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $220.0 to $250.0 for Apple over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Apple's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Apple's whale activity within a strike price range from $220.0 to $250.0 in the last 30 days. </p>
<h3>Apple Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736952348_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AAPL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/31/25</td>
<td>$3.15</td>
<td>$3.1</td>
<td>$3.15</td>
<td>$230.00</td>
<td>$88.2K</td>
<td>7.2K</td>
<td>294</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/24/25</td>
<td>$4.3</td>
<td>$4.15</td>
<td>$4.23</td>
<td>$235.00</td>
<td>$72.7K</td>
<td>5.3K</td>
<td>196</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.05</td>
<td>$2.94</td>
<td>$3.0</td>
<td>$235.00</td>
<td>$52.9K</td>
<td>44.4K</td>
<td>1.9K</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$1.96</td>
<td>$1.95</td>
<td>$1.96</td>
<td>$237.50</td>
<td>$41.8K</td>
<td>10.2K</td>
<td>11.0K</td>
</tr>
<tr>
<td>AAPL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/14/25</td>
<td>$2.11</td>
<td>$2.05</td>
<td>$2.05</td>
<td>$220.00</td>
<td>$40.9K</td>
<td>848</td>
<td>13</td>
</tr>
</tbody>
</table>
</p>
<h3>About Apple</h3>
<p>Apple is among the largest companies in the world, with a broad portfolio of hardware and software products targeted at consumers and businesses. Apple's iPhone makes up a majority of the firm sales, and Apple's other products like Mac, iPad, and Watch are designed around the iPhone as the focal point of an expansive software ecosystem. Apple has progressively worked to add new applications, like streaming video, subscription bundles, and augmented reality. The firm designs its own software and semiconductors while working with subcontractors like Foxconn and TSMC to build its products and chips. Slightly less than half of Apple's sales come directly through its flagship stores, with a majority of sales coming indirectly through partnerships and distribution.</p>
<h3>Current Position of Apple</h3>
<ul>
<li>Trading volume stands at 1,307,826, with AAPL's price up by 0.85%, positioned at $235.26.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 15 days.</li>
</ul>
<h3>What Analysts Are Saying About Apple</h3>
<p>A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $257.25.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Buy rating on Apple with a target price of $256.<br />
&#x2A; An analyst from MoffettNathanson downgraded its action to Sell with a price target of $188.<br />
&#x2A; Maintaining their stance, an analyst from Bernstein continues to hold a Outperform rating for Apple, targeting a price of $260.<br />
&#x2A; Maintaining their stance, an analyst from Wedbush continues to hold a Outperform rating for Apple, targeting a price of $325. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Apple, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

AAPL

Decoding Apple's Options Activity: What's the Big Picture?

<p>Deep-pocketed investors have adopted a bullish approach towards Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in TSLA usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 189 extraordinary options activities for Tesla. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 45% leaning bullish and 40% bearish. Among these notable options, 30 are puts, totaling $1,963,974, and 159 are calls, amounting to $9,808,206.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $200.0 and $700.0 for Tesla, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Tesla's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Tesla's significant trades, within a strike price range of $200.0 to $700.0, over the past month.</p>
<h3>Tesla Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736952343_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$16.5</td>
<td>$16.25</td>
<td>$16.5</td>
<td>$400.00</td>
<td>$460.3K</td>
<td>31.5K</td>
<td>2.9K</td>
</tr>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$10.15</td>
<td>$9.95</td>
<td>$10.05</td>
<td>$410.00</td>
<td>$326.8K</td>
<td>15.0K</td>
<td>12.1K</td>
</tr>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$11.2</td>
<td>$11.05</td>
<td>$11.05</td>
<td>$410.00</td>
<td>$216.7K</td>
<td>15.0K</td>
<td>9.6K</td>
</tr>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$6.45</td>
<td>$6.3</td>
<td>$6.34</td>
<td>$420.00</td>
<td>$214.0K</td>
<td>20.8K</td>
<td>10.7K</td>
</tr>
<tr>
<td>TSLA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$26.95</td>
<td>$26.7</td>
<td>$26.7</td>
<td>$400.00</td>
<td>$203.1K</td>
<td>14.1K</td>
<td>137</td>
</tr>
</tbody>
</table>
</p>
<h3>About Tesla</h3>
<p>Tesla is a vertically integrated battery electric vehicle automaker and developer of autonomous driving software. The company has multiple vehicles in its fleet, which include luxury and midsize sedans, crossover SUVs, a light truck, and a semi truck. Tesla also plans to begin selling more affordable vehicles, a sports car, and a robotaxi. Global deliveries in 2024 were a little below 1.8 million vehicles. The company sells batteries for stationary storage for residential and commercial properties including utilities and solar panels and solar roofs for energy generation. Tesla also owns a fast-charging network.</p>
<p>In light of the recent options history for Tesla, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Tesla's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 4,752,458, the TSLA's price is up by 3.17%, now at $408.91. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 14 days.</li>
</ul>
<h3>Expert Opinions on Tesla</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $350.372.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from GLJ Research downgraded its action to Sell with a price target of $24.<br />
&#x2A; Consistent in their evaluation, an analyst from Canaccord Genuity keeps a Buy rating on Tesla with a target price of $404.<br />
&#x2A; An analyst from Baird has decided to maintain their Outperform rating on Tesla, which currently sits at a price target of $480.<br />
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Hold rating on Tesla with a target price of $351.<br />
&#x2A; An analyst from Stifel has decided to maintain their Buy rating on Tesla, which currently sits at a price target of $492. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Tesla options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


TSLA

Tesla Unusual Options Activity

<p>Financial giants have made a conspicuous bullish move on Vistra. Our analysis of options history for Vistra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) revealed 14 unusual trades.</p>
<p>Delving into the details, we found 35% of traders were bullish, while 35% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $90,150, and 11 were calls, valued at $694,321.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $110.0 to $200.0 for Vistra over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Vistra options trades today is 1315.18 with a total volume of 1,374.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Vistra's big money trades within a strike price range of $110.0 to $200.0 over the last 30 days.</p>
<h3>Vistra Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736952337_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>VST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$10.85</td>
<td>$10.0</td>
<td>$10.0</td>
<td>$200.00</td>
<td>$200.0K</td>
<td>1.0K</td>
<td align="right">0</td>
</tr>
<tr>
<td>VST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/24/25</td>
<td>$5.0</td>
<td>$4.9</td>
<td>$5.0</td>
<td>$180.00</td>
<td>$100.3K</td>
<td>2.3K</td>
<td align="right">10</td>
</tr>
<tr>
<td>VST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/24/25</td>
<td>$7.5</td>
<td>$7.25</td>
<td>$7.25</td>
<td>$175.00</td>
<td>$72.5K</td>
<td>236</td>
<td align="right">233</td>
</tr>
<tr>
<td>VST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$18.8</td>
<td>$18.8</td>
<td>$18.8</td>
<td>$155.00</td>
<td>$67.6K</td>
<td>4.7K</td>
<td align="right">37</td>
</tr>
<tr>
<td>VST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/24/25</td>
<td>$4.85</td>
<td>$4.6</td>
<td>$4.85</td>
<td>$180.00</td>
<td>$53.6K</td>
<td>2.3K</td>
<td align="right">277</td>
</tr>
</tbody>
</table>
</p>
<h3>About Vistra</h3>
<p>Vistra Energy is one of the largest power producers and retail energy providers in the us Following the 2024 Energy Harbor acquisition, Vistra owns 41 gigawatts of nuclear, coal, natural gas, and solar power generation along with one of the largest utility-scale battery projects in the world. Its retail electricity business serves 5 million customers in 20 states, including almost a third of all Texas electricity consumers. Vistra emerged from the Energy Future Holdings bankruptcy as a stand-alone entity in 2016. It acquired Dynegy in 2018.</p>
<p>After a thorough review of the options trading surrounding Vistra, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Current Position of Vistra</h3>
<ul>
<li>Trading volume stands at 309,403, with VST's price up by 3.04%, positioned at $175.69.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 42 days.</li>
</ul>
<h3>What Analysts Are Saying About Vistra</h3>
<p>A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $174.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Buy rating for Vistra, targeting a price of $174. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Vistra with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Check Out What Whales Are Doing With VST

<p>Scotiabank  analyst Eric Winmill   reinstates Metalla Royalty (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MTA#AMEX">MTA</a>) with a Sector Perform and announces $4.5 price target.</p>


Initiation

Scotiabank Reinstates Sector Perform on Metalla Royalty, Announces $4.5 Price Target

<p>There's no shortage of headlines about <a href="https://www.benzinga.com/startups/24/01/36724158/warren-buffetts-investment-prot-g-grew-his-retirement-fund-from-70-000-to-264-million-an-account-he">people mimicking Warren Buffett's portfolio</a> and striking gold. The idea seems simple enough: Buffett buys Apple, you buy Apple. He sells a bank stock, you do the same. Why not ride the coattails of one of the richest and most successful investors in the world? On a smaller scale, it might even make sense – after all, if it worked for him, why wouldn't it work for you?</p>
<p>But Buffett himself has weighed in on this strategy and the answer might surprise you. During the 2009 Berkshire Hathaway Annual Meeting, a shareholder asked a bold question: why shouldn't investors just sell their Berkshire Hathaway shares and directly copy his moves?</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/money/advisor-adv-warren-buffett">Warren Buffett Flipped His Neighbor's $67,000 Life Savings Into A $50 Million Fortune — This Would Be Worth Over $500 Million Today</a></strong></li>
<li><strong><a href="https://www.benzinga.com/money/qnetic-2">This 12,000 RPM Spinning Battery With Over $100 Million In LOIs Could Be The Missing Link For Green Energy — Here&#8217;s Why Early Investors Are Flocking To Invest Before Funding Closes</a></strong></li>
</ul>
<p>"[In terms of buying what we're buying], others can't buy with free float, although they may have tax advantages we don't have," Buffett explained, referencing the unique advantages Berkshire Hathaway enjoys due to its structure. "We don't quarrel with those who buy what we buy. You can piggyback, but you can't <a href="https://www.benzinga.com/personal-finance/24/11/41818744/warren-buffett-bought-a-1-7-billion-business-over-the-phone-without-meeting-founder-by-using-wha">buy the [whole] businesses</a> we do."</p>
<p>His longtime business partner <a href="https://www.benzinga.com/personal-finance/24/11/41810582/charlie-munger-warned-its-a-b-tch-but-you-gotta-do-it-your-100-000-is-the-hardest-but-the-most-i">Charlie Munger</a> added: "It's generally quite smart to copy very successful investors."</p>
<p>Buffett himself admitted, "I did the same thing when I was young."</p>
<p>But does that mean replicating Buffett's investments is a foolproof way to build wealth? Not exactly.</p>
<p><strong>See Also: ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>You can invest today for just $0.26/share with a $1000 minimum.</strong></a></strong></p>
<p><strong>The Pitfalls of Copycat Investing</strong></p>
<p>While Buffett doesn't outright dismiss the idea, he clarifies that mimicking his portfolio isn't a perfect strategy. One key reason is scale. Berkshire Hathaway doesn't just buy shares – it often buys entire businesses. This gives the company leverage, operational control and economies of scale that an individual investor can't replicate.</p>
<p>Buffett's moves are often tied to advantages unique to Berkshire, such as the "free float" from its insurance businesses. This allows the company to invest without the same financial constraints an individual might face.</p>
<p>Another factor is timing. By the time Buffett's trades become public, market conditions may have shifted. You're often playing catch-up, which means you might not reap the same benefits from the investments he makes.</p>
<p><strong>Trending: With 100+ historic trademarks including some of the high grossing characters in history, like Cinderella, Snow White and Peter Pan, <a href="https://www.benzinga.com/money/elf-labs-1"><strong>this company is transforming the $2 trillion entertainment market with patented AR, VR, and AI tech. — For a short window, investors are able to claim $2/share ($980 min).</strong></a></strong></p>
<p><strong>What About the Upside?</strong></p>
<p>Still, there's merit to learning from Buffett's choices. As Munger pointed out, copying successful investors is "generally quite smart." Buffett studied his mentor Benjamin Graham and learned from other great investors during his early years. Analyzing Buffett's portfolio can provide insights into how he evaluates companies and what he considers a good value.</p>
<p>However, blindly following his trades isn't the same as understanding his strategy. Buffett's approach is deeply rooted in fundamental analysis, long-term thinking and an ability to evaluate businesses, not just stocks. Without that underlying knowledge, copying his moves could be risky.</p>
<p>Observing and learning from his decisions can offer valuable lessons, but the most important takeaway might be to develop your own investing philosophy.</p>
<p>Buffett and the late Munger would likely agree for those aspiring to follow in his footsteps: don't just imitate – educate. That's the true key to long-term success. And if you need a little extra help building your investment strategy, consider <a href="https://www.benzinga.com/money/are-you-rich">consulting a financial advisor</a>. They can guide you in making informed decisions tailored to your financial goals and risk tolerance. After all, the best investment approach is one that works for you.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"><strong> </strong><strong>Tax deferring is their number one strategy</strong></a>.</strong></li>
<li><strong>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</strong></a></strong></li>
</ul>


Personal Finance

Warren Buffett Has Advice For People Trying To Get Rich By Copying His Moves: 'You Can Piggyback, But You Can't Buy the Whole Businesses'

<p>Imperial Oil (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IMO#AMEX">IMO</a>) has outperformed the market over the past 5 years by 8.57% on an annualized basis producing an average annual return of 20.8%. Currently, Imperial Oil has a market capitalization of $36.16 billion. </p>
<p><strong>Buying $1000 In IMO:</strong> If an investor had bought $1000 of IMO stock 5 years ago, it would be worth <strong>$2,572.63</strong> today based on a price of $67.48 for IMO at the time of writing.</p>
<h3>Imperial Oil's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736952309_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much You Would Have Made Owning Imperial Oil Stock In The Last 5 Years

<p>Evercore ISI Group  analyst Stephen Richardson   maintains TechnipFMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTI#NYSE">FTI</a>) with a Outperform and raises the price target from $37 to $39.</p>


Evercore ISI Group Maintains Outperform on TechnipFMC, Raises Price Target to $39

<p>RBC Capital  analyst Leonid Timashev   reiterates Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) with a Outperform and maintains $18 price target.</p>


Reiteration

CMPS

RBC Capital Reiterates Outperform on Compass Pathways, Maintains $18 Price Target

SGBX

Safe & Green Holdings Shares Resume Trade

PTLE

PTL Shares Halted On Circuit Breaker To The Upside, Stock Now Down -17.2%

IONQ

LAES

QBTS

QUBT

RGTI

Shares of quantum companies are trading higher after Microsoft issued a statement to its business customers to get "quantum ready" and Nvidia announced its first ever quantum day event.

OSTX

OS Therapies Shares Resume Trade

<p>Evercore ISI Group  analyst James West   maintains Baker Hughes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) with a Outperform and raises the price target from $46 to $52.</p>


Evercore ISI Group Maintains Outperform on Baker Hughes, Raises Price Target to $52

<p>RBC Capital  analyst Scott Hanold   reiterates APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) with a Sector Perform and maintains $32 price target.</p>


RBC Capital Reiterates Sector Perform on APA, Maintains $32 Price Target

Eupraxia Pharmaceuticals (TSE:EPRX) has released an update. Eupraxia Pharmaceuticals is set to showcase its innovative drug delivery solutions at t...

Eupraxia Pharmaceuticals Showcases Innovations in Drug Delivery

Eupraxia Pharmaceuticals (TSE:EPRX) has released an update. Eupraxia Pharmaceuticals has successfully raised C$44.5 million through a non-brokered ...

Eupraxia Pharmaceuticals Secures C$44.5 Million Investment

Eupraxia Pharmaceuticals (TSE:EPRX) has released an update. Eupraxia Pharmaceuticals reported advances in its clinical trials and financial results...

Eupraxia Pharmaceuticals Reports Q3 Progress and Funding

Eupraxia Pharmaceuticals (EPRX)announced additional positive clinical data from its RESOLVE Phase 1b/2a trial, which is evaluating the safety and e...

Eupraxia reports data from RESOLVE Phase 1b/2a trial

Eupraxia Pharmaceuticals (TSE:EPRX) has released an update. Eupraxia Pharmaceuticals has announced promising results from their RESOLVE trial for t...

Eupraxia Pharmaceuticals Reports Promising Trial Results

Eupraxia Pharmaceuticals (TSE:EPRX) has released an update. Eupraxia Pharmaceuticals is hosting a webinar on November 15, 2024, focusing on Eosinop...

Eupraxia Pharmaceuticals Hosts Webinar on Digestive Disorders

Rodman & Renshaw analyst Brandon Folkes initiated coverage of Eupraxia Pharmaceuticals (EPRX) with a Buy rating and $9 price target Eupraxia is a d...

Eupraxia Pharmaceuticals  initiated with a Buy at Rodman & Renshaw

Eupraxia Pharmaceuticals (TSE:EPRX) has released an update. Eupraxia Pharmaceuticals is set to present its promising EP-104IAR study at the prestig...

Eupraxia Pharmaceuticals Showcases Innovation at ACR 2024

Eupraxia Pharmaceuticals (EPRX)unveiled new pharmacokinetic, or PK data from its Phase 2a Eosinophilic Esophagitis, or EoE, program. Management bel...

Eupraxia presents new PK data from its Phase 2a Eosinophilic Esophagitis program

Eupraxia Pharmaceuticals (TSE:EPRX) has released an update. Eupraxia Pharmaceuticals has revealed promising pharmacokinetic data for its DiffuSpher...

Eupraxia Pharmaceuticals Unveils Promising Drug Delivery Data

Press Releases

Eupraxia Pharmaceuticals Strengthens Senior Management Team

Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024

Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis

Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024

Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million

Earnings

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months

TSX:BRE

TSX:EPRX

Rodman & Renshaw

Comments

Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals (EPRX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga